Skip to content

Join us at this webinar you will hear from our 3 panelists discuss regulatory, technology and scientific perspectives to gain insights, into accelerating your compound through the clinical development pipeline with a focus on retina.

A man writing something in a notebook


Case Studies

View all

Quantitative Fibroblast-to-Myofibroblast Transition (FMT) studies

Quantitative FMT assay with high content imaging

Find out more
Human Lung Fibroblasts stimulated with TGF-β for 72 hours and immunostained to detect α-SMA, as a measure of extracellular matrix production and deposition.

In vitro evaluation of ocular toxicity and phenotypic rescue

Find out more
Newcells Biotech to develop 3D retinal organoids using hiPSC derived skin cells

In vitro selection of the most relevant species to predict human renal toxicity

Find out more
A microscope image of a nephron model

Evaluation of glomerular ADC toxicity in podocytes

Find out more

Get our latest updates straight to your inbox